Central Bank & Trust’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Central Bank & Trust’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,608	Closed	-$22.2K	–	368
2024 Q2	$22.2K	Hold	7,608	–	–	﹤0.01%	281
2024 Q1	$24.3K	Hold	7,608	–	–	﹤0.01%	266
2023 Q4	$25.5K	Hold	7,608	–	–	﹤0.01%	272
2023 Q3	$18K	Hold	7,608	–	–	﹤0.01%	263
2023 Q2	$13.3K	Hold	7,608	–	–	﹤0.01%	269
2023 Q1	$23.4K	Hold	7,608	–	–	﹤0.01%	250
2022 Q4	$40.3K	Hold	7,608	–	–	0.01%	237
2022 Q3	$27K	Hold	7,608	–	–	0.01%	238
2022 Q2	$20K	Hold	7,608	–	–	﹤0.01%	258
2022 Q1	$34K	Hold	7,608	–	–	0.01%	241
2021 Q4	$52K	Buy	7,608 +7,155	+1,579%	+$48.7K	0.01%	227
2021 Q3	$3K	Hold	453	–	–	﹤0.01%	298
2021 Q2	$5K	Hold	453	–	–	﹤0.01%	283
2021 Q1	$4K	Buy	+453	New	+$4.44K	﹤0.01%	279

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Central Bank & Trust's PSTX Position: Q3 2024 in Review

Central Bank & Trust sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2024, closing a stake of 7,608 shares — an estimated $22.2K sold.

Central Bank & Trust first reported a position in PSTX in Q1 2021 and held it in 14 quarters. The position peaked at $52K in Q4 2021. 96 funds tracked by Wall St. Rank hold PSTX as of Q3 2024.

Central Bank & Trust reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 7,608 Poseida Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $22.2K.
Central Bank & Trust first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
Central Bank & Trust's Poseida Therapeutics, Inc. Common Stock position peaked at $52K in Q4 2021.
96 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.